Argenx’s Autoimmune Disease Blockbuster-In-Waiting Gets FDA Decision Date

Myasthenia Gravis Is First Target

 
• By Andrew McConaghie

The Belgium-Netherlands based company looks on course to gain US approval by the end of 2021.

Myasthenia gravis
Myasthenia gravis causes muscle weakness, typically affecting the eyes and face.

More from Business

More from Scrip